Topics:

Biweekly Capecitabine Schedule Feasible

Biweekly Capecitabine Schedule Feasible

ASCO—A biweekly dosing regimen of capecitabine (Xeloda) was well tolerated in a dose-escalation study of metastatic breast cancer patients, allowing safe delivery of higher daily doses than routinely used in practice, Maria Theodoulou, MD, Memorial Sloan-Kettering Cancer Center, reported at the ASCO 2007 meeting (abstract 1045). Capecitabine is typically delivered on a 14-days-on/7-days-off schedule at 1,250 mg/m2 twice daily (total of 2,500 mg/m2/d). In the current study, the agent was given on a 7-days-on/7-days-off schedule with a maximum tolerated dose of 2,000 mg/m2 twice daily (total of 4,000 mg/m2/d).

The design of the single-center, open-label, phase I/II study was based on Norton-Simon mathematical modeling that predicted the optimal dosing schedule for capecitabine. There were no grade 4-5 toxicities, and grade 3 toxicities were transient and manageable. "This new dosing regimen for capecitabine will serve as a platform for combination treatment with targeted therapies," said lead author Clifford Hudis, MD, chief of the Breast Cancer Medicine Service.

 
Loading comments...
Please Wait 20 seconds or click here to close